Selected article for: "CAP value and lobeglitazone responder"
Author: Lee, Yong-ho; Kim, Jae Hyeon; Kim, So Ra; Jin, Heung Yong; Rhee, Eun-Jung; Cho, Young Min; Lee, Byung-Wan
Title: Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
  • Document date: 2016_11_8
    • ID: 4fwp1dnl_18
    Snippet: To assess whether the improvement in hepatic steatosis was associated with better glycemic control, we examined changes in CAP and HbA1C values in patients according to their lobeglitazone responsiveness (Fig. 2C and 2D ). After the 24-week treatment, the mean CAP value in the lobeglitazone-responder group decreased from 320.9 dB/m to 282.6 dB/m, whereas the mean CAP value in the lobeglitazone-non-responder group increased from 299. These data in.....
    Document: To assess whether the improvement in hepatic steatosis was associated with better glycemic control, we examined changes in CAP and HbA1C values in patients according to their lobeglitazone responsiveness (Fig. 2C and 2D ). After the 24-week treatment, the mean CAP value in the lobeglitazone-responder group decreased from 320.9 dB/m to 282.6 dB/m, whereas the mean CAP value in the lobeglitazone-non-responder group increased from 299. These data indicate that the improvement in hepatic steatosis by lobeglitazone is independent of its glucose-lowering effect. Changes in glycemic, lipid, and hepatic profiles after lobeglitazone treatment for 24 weeks Among secondary endpoints, the 24-week treatment with lobeglitazone significantly improved glycemic parameters, such as GA and the fasting levels of glucose and insulin (P < 0.001) ( Table 2 ). Insulin resistance, as assessed by HOMAIR, was ameliorated from 5.5 to 3.4 by lobeglitazone treatment. Among lipid profile components, lobeglitazone treatment significantly increased HDL-C (P = 0.001) and decreased TG levels (P = 0.019). However, TC and LDL-C levels did not change. All components of the hepatic profile, including AST, ALT, and γGTP, showed significantly decreased levels after 24 weeks of treatment (P < 0.01). In addition, LSM and hsCRPs values were marginally decreased, whereas average body weight increased by 1.4 kg after lobeglitazone treatment. At the 24-week time point, drug compliance was 98.2%.

    Search related documents:
    Co phrase search for related documents
    • average body weight and glucose lower: 1
    • average body weight and glycemic control: 1, 2
    • average body weight and hepatic steatosis: 1
    • average body weight and hepatic steatosis improvement: 1
    • average body weight kg increase and body weight: 1, 2, 3
    • average body weight kg increase and glycemic control: 1
    • average body weight kg increase and hepatic steatosis: 1
    • average body weight kg increase and hepatic steatosis improvement: 1
    • body weight and fast level: 1
    • body weight and glucose lower: 1, 2, 3, 4, 5, 6, 7, 8
    • body weight and glycemic control: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • body weight and HbA1C value: 1
    • body weight and hepatic steatosis: 1, 2, 3, 4, 5, 6, 7
    • body weight and hepatic steatosis improvement: 1
    • CAP value and HbA1C value: 1
    • CAP value and hepatic steatosis: 1
    • glucose lower and glycemic control: 1, 2, 3, 4, 5
    • glycemic control and HbA1C value: 1, 2, 3, 4, 5, 6
    • glycemic control and hepatic steatosis: 1, 2, 3, 4, 5, 6